FDA clears first ready-to-use insulin for IV infusion

July 22, 2019

FDA approved the first and only ready-to-use insulin for IV infusion in hospitals and acute care settings.

FDA approved the first and only ready-to-use insulin for IV infusion in hospitals and acute care settings.

Insulin Human in 0.9% Sodium Chloride Injection (Myxredlin, Baxter), which treats diabetes mellitus in both adult and pediatric patients, has an extended shelf life of 30 days at room temperature or 24 months if refrigerated in the original carton to protect from light, according to Baxter.

Related: Cybersecurity Glitch Wreaks Havoc On Insulin Pump

“Insulin is in the top 5 drug classes involved with medication errors, and more than 30 of those errors result in patient harm,” said Robert Felicelli, president of Pharmaceuticals at Baxter, in a press release from the company. “When a patient requires intravenous insulin in the hospital, pharmacists have to manually admix insulin for treatment. With the launch of Myxredlin, clinicians will have access to a convenient, reliable presentation of ready-to-use insulin that can help ensure faster delivery to patients, streamlined workflow for pharmacists and nurses, and less waste for hospitals."

Baxter expects the new IV insulin to be available by the end of the year

Related: Pharm Maker, PBMs Lower Insulin Prices

Myxredlin is provided in a standardized concentration of 100 units/100 ml in a flexible plastic container. “This innovative presentation helps ensure Myxredlin delivers a consistent, stable and predictable concentration with every administration, which is a key consideration for patient safety,” Baxter said.

Read more: Lack of Insulin Competition High Priority For FDA